• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

小儿肉瘤的伊立替康治疗十五年：下一步何去何从？

Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?

作者信息

Wagner Lars M

机构信息

Division of Pediatric Hematology/Oncology, Kentucky Clinic Suite, University of Kentucky, J-457, Lexington, KY 40536 USA.

出版信息

Clin Sarcoma Res. 2015 Aug 28;5:20. doi: 10.1186/s13569-015-0035-x. eCollection 2015.

DOI:10.1186/s13569-015-0035-x
PMID:26322224
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4552408/
Abstract

Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents.

摘要

在过去15年里，伊立替康已成为治疗小儿肉瘤患者的一种重要药物。本综述总结了既往研究中观察到的活性，并概述了关于给药方案、给药途径和副作用改善方面的当前问题。还讨论了伊立替康及其活性代谢产物SN-38的新型聚乙二醇化和纳米脂质体制剂，以及伊立替康与其他传统细胞毒性药物和靶向药物联合使用的未来计划。

相似文献

1
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?小儿肉瘤的伊立替康治疗十五年：下一步何去何从？
Clin Sarcoma Res. 2015 Aug 28;5:20. doi: 10.1186/s13569-015-0035-x. eCollection 2015.
2
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.STA-8666是一种新型的热休克蛋白90（HSP90）抑制剂与SN-38的药物偶联物，在儿童肉瘤的临床前小鼠模型中可导致肿瘤完全消退。
Oncotarget. 2016 Oct 4;7(40):65540-65552. doi: 10.18632/oncotarget.11869.
3
Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.MM-398（纳米脂质体伊立替康，nal-IRI）在尤文氏家族肿瘤异种移植物中的活性与药物对肿瘤的高暴露和高 SLFN11 表达有关。
Clin Cancer Res. 2015 Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.
4
Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.长春新碱、伊立替康和替莫唑胺治疗难治性/复发性小儿实体瘤：单中心经验
J Oncol Pharm Pract. 2019 Sep;25(6):1343-1348. doi: 10.1177/1078155218790798. Epub 2018 Aug 6.
5
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.曲贝替定与伊立替康联合使用对人横纹肌肉瘤异种移植瘤具有高效性。
Anticancer Drugs. 2005 Sep;16(8):811-5. doi: 10.1097/01.cad.0000172837.67766.6a.
6
Camptothecin-based regimens for treatment of ewing sarcoma: past studies and future directions.基于喜树碱的尤文肉瘤治疗方案：既往研究与未来方向
Sarcoma. 2011;2011:957957. doi: 10.1155/2011/957957. Epub 2011 Apr 6.
7
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.儿童肿瘤学组开展的两项关于伊立替康单药或联合长春新碱治疗转移性横纹肌肉瘤的连续II期探索性试验。
J Clin Oncol. 2007 Feb 1;25(4):362-9. doi: 10.1200/JCO.2006.07.1720.
8
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.伊立替康用于儿童实体瘤：纪念斯隆凯特琳癌症中心的经验
J Pediatr Hematol Oncol. 2002 Feb;24(2):101-5. doi: 10.1097/00043426-200202000-00009.
9
Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.纳米脂质体伊立替康的临床前活性由肿瘤沉积和肿瘤内前药转化决定。
Cancer Res. 2014 Dec 1;74(23):7003-13. doi: 10.1158/0008-5472.CAN-14-0572. Epub 2014 Oct 1.
10
A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study.CPT-11（伊立替康）在高危尤文肉瘤中的 II 期窗研究：一项欧洲尤文肉瘤研究。
Pediatr Blood Cancer. 2014 Mar;61(3):442-5. doi: 10.1002/pbc.24767. Epub 2013 Sep 9.

引用本文的文献

1
Managing Irinotecan-Induced Diarrhea: A Comprehensive Review of Therapeutic Interventions in Cancer Treatment.管理伊立替康所致腹泻：癌症治疗中治疗干预措施的全面综述
Pharmaceuticals (Basel). 2025 Mar 2;18(3):359. doi: 10.3390/ph18030359.
2
Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma.艾瑞布林单药治疗或与伊立替康联合治疗小儿横纹肌肉瘤、非横纹肌肉瘤软组织肉瘤或尤因肉瘤患者的疗效、安全性及药代动力学。
ESMO Open. 2025 Feb;10(2):104129. doi: 10.1016/j.esmoop.2024.104129. Epub 2025 Feb 4.
3
Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma.在滑膜肉瘤中，SN38通过抑制TWIST1提高组蛋白去乙酰化酶抑制剂的疗效。
Cancer Innov. 2024 Apr 8;3(2):e113. doi: 10.1002/cai2.113. eCollection 2024 Apr.
4
Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis.伊立替康所致腹泻的防护干预措施的效果：系统评价和荟萃分析。
Integr Cancer Ther. 2024 Jan-Dec;23:15347354241242110. doi: 10.1177/15347354241242110.
5
The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma.药物代谢酶在调节治疗横纹肌肉瘤药物的治疗效果中的作用
Cancers (Basel). 2024 Feb 29;16(5):1012. doi: 10.3390/cancers16051012.
6
Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates.拓扑异构酶I抑制剂在间充质恶性肿瘤治疗中的当前作用及其作为肉瘤特异性抗体药物偶联物有效载荷的潜在未来应用。
Oncol Res Treat. 2024;47(1-2):18-41. doi: 10.1159/000535491. Epub 2023 Nov 28.
7
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies.横纹肌肉瘤：当前的治疗方法、挑战及未来的治疗策略途径
Cancers (Basel). 2023 Nov 2;15(21):5269. doi: 10.3390/cancers15215269.
8
Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.III 期低危 Wilms 瘤中淋巴结侵犯和 1p 或 16q 杂合性缺失的预后影响：来自儿童肿瘤学组 AREN03B2 和 AREN0532 研究的报告。
Cancer. 2024 Mar 1;130(5):792-802. doi: 10.1002/cncr.35084. Epub 2023 Oct 30.
9
DICER1-associated central nervous system sarcoma: A comprehensive clinical and genomic characterization of case series of young adult patients.与DICER1相关的中枢神经系统肉瘤：年轻成年患者病例系列的综合临床和基因组特征分析
Neurooncol Pract. 2023 Mar 19;10(4):381-390. doi: 10.1093/nop/npad014. eCollection 2023 Aug.
10
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.儿科 WEE1 抑制剂adavosertib（AZD1775）联合伊立替康治疗神经母细胞瘤、髓母细胞瘤和横纹肌肉瘤的 2 期临床试验。
Cancer. 2023 Jul 15;129(14):2245-2255. doi: 10.1002/cncr.34786. Epub 2023 Apr 20.

本文引用的文献

1
Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.MM-398（纳米脂质体伊立替康，nal-IRI）在尤文氏家族肿瘤异种移植物中的活性与药物对肿瘤的高暴露和高 SLFN11 表达有关。
Clin Cancer Res. 2015 Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.
2
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.在儿科临床前测试项目的儿科癌症模型中，他拉唑帕尼（BMN 673）与替莫唑胺联合抑制PARP的协同活性。
Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10.
3
Targeting the DNA repair pathway in Ewing sarcoma.靶向尤因肉瘤中的DNA修复途径。
Cell Rep. 2014 Nov 6;9(3):829-41. doi: 10.1016/j.celrep.2014.09.028. Epub 2014 Oct 23.
4
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.奥拉帕利用于标准化疗失败后的难治性尤因肉瘤患者的II期研究。
BMC Cancer. 2014 Nov 5;14:813. doi: 10.1186/1471-2407-14-813.
5
Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.纳米脂质体伊立替康的临床前活性由肿瘤沉积和肿瘤内前药转化决定。
Cancer Res. 2014 Dec 1;74(23):7003-13. doi: 10.1158/0008-5472.CAN-14-0572. Epub 2014 Oct 1.
6
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.口服吉非替尼和伊立替康治疗耐药性实体瘤儿童的 I 期剂量递增和药代动力学研究。
Cancer Chemother Pharmacol. 2014 Dec;74(6):1191-8. doi: 10.1007/s00280-014-2593-7. Epub 2014 Sep 26.
7
Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: a single-center experience and review of the literature.伊立替康与替莫唑胺治疗复发性尤因肉瘤：单中心经验及文献综述
Pediatr Hematol Oncol. 2015 Feb;32(1):50-9. doi: 10.3109/08880018.2014.954070. Epub 2014 Sep 24.
8
A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.多西他赛与伊立替康用于复发性或难治性尤因肉瘤家族性肿瘤儿童和青年患者的研究。
BMC Cancer. 2014 Aug 28;14:622. doi: 10.1186/1471-2407-14-622.
9
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.EZN-2208（一种伊立替康聚乙二醇偶联物）在复发或难治性实体瘤的儿童、青少年和年轻成人中的 1 期评估。
Pediatr Blood Cancer. 2014 Oct;61(10):1792-7. doi: 10.1002/pbc.25105. Epub 2014 Jun 24.
10
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.替西罗莫司联合伊立替康和替莫唑胺治疗复发或难治性实体瘤患儿、青少年和年轻成人的 1 期临床试验：一项儿童肿瘤学组研究。
Pediatr Blood Cancer. 2014 May;61(5):833-9. doi: 10.1002/pbc.24874. Epub 2013 Nov 19.